TARRYTOWN, N.Y.--(BUSINESS WIRE)--PsychoGenics Inc. and Dainippon Sumitomo Pharma, Co., Ltd., Japan, have entered into a drug discovery agreement to screen selected Dainippon Sumitomo Pharma compounds in PsychoGenics’ proprietary Drug Discovery Systems, with the aim of identifying new therapies for CNS disorders.
